Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

IntroductionPlatinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing on the role of immuno checkpoint inhibitor (ICI) based treatments for...

Full description

Bibliographic Details
Main Authors: Yujing Li, Haohua Jiang, Fangfei Qian, Ya Chen, Wensheng Zhou, Yanwei Zhang, Jun Lu, Yuqing Lou, Baohui Han, Wei Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
non-small-cell lung cancer
immunotherapy
drug resistance
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
programmed death ligand 1 (PD-L1)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1161718/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1161718/full

Similar Items